Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Stefan T PetersonDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-2984-6400
Katherine G Dailey *Division of Infectious Diseases, Brigham and Women's Hospital, Boston, USA.
Karthik Hullahalli *Division of Infectious Diseases, Brigham and Women's Hospital, Boston, USA.ORCID 0000-0003-3064-2090
Daniel SorobeteaDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0009-0008-6248-449X
Rina MatsudaDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-8279-5788
Jaydeen SewellDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Winslow YostDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0009-0002-8012-972X
Rosemary O'NeillDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0009-0009-7130-2480
Suhas BobbaDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-9276-1469
Nicolai ApenesDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-1134-1890
Matthew E ShermanDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
George I BalazsDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, USA.ORCID 0009-0008-6192-7041
Charles-Antoine AssenmacherDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Arin CoxDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-1841-8512
Matthew LanzaDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-5477-3549
Sunny ShinDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0001-5214-9577
Matthew K WaldorDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, USA.ORCID 0000-0003-1843-7000
Igor E BrodskyDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0001-7970-872X
Funding
UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Robert H. Vonderheide · 1985 to 2026
$222.3M
Vibrio cholerae intestinal colonization and vaccine developmentR01AI042347 · NIAID · TUFTS UNIVERSITY BOSTON · PI WALDOR, MATTHEW K · 1998 to 2025
$7.3M
Defining the mechanism and functions of RIPK1-induced cell death in anti-bacterial immune defenseR01AI139102 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BRODSKY, IGOR E · 2019 to 2023
$2.8M
Training CoreTL1DK143326 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Wei Tong · 2024 to 2026
$2.5M
Dissecting innate immune control of intestinal and systemic Yersinia infectionR01AI191440 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI IGOR E BRODSKY, Sunny Shin · 2025 to 2026
$2.1M
Defining the non-apoptotic role of Caspase-8 activity in anti-bacterial immune defenseR01AI128530 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BRODSKY, IGOR E · 2017 to 2021
$2.0M
Lymphothrombosis in gut health and diseaseR01DK123528 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI BRODSKY, IGOR E, KAHN, MARK L · 2019 to 2023
$2.0M
Training in Microbial Pathogenesis and GenomicsT32AI141393 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI GOULIAN, MARK D, ZHU, JUN · 2019 to 2023
$1.3M
Aperio VERSA Digital Slide Scanner, eSlide Manager Database, and Advanced Image Analysis SoftwareS10OD023465 · OD · UNIVERSITY OF PENNSYLVANIA · PI DURHAM, AMY CLEVELAND · 2018 to 2018
$329k
Broad InstituteBurroughs Wellcome Fund PATHCenter for Integrated Solutions for Infectious DiseasesHoward Hughes Medical InstituteNational Institute of Allergy and Infectious DiseasesNational Institute of Allergy and Infectious Diseases 1R01AI191440National Institute of Allergy and Infectious Diseases F31AI16074National Institute of Allergy and Infectious Diseases R01AI139102A1, 1R01AI128530, 1R01AI191440National Institute of Allergy and Infectious Diseases T32 AI141393-2National Science Foundation Graduate Research Fellowship ProgramNCI NIH HHS P30CA01652NCI NIH HHS P30 CA016520NIAID NIH HHS R01 AI042347NIAID NIH HHS R01 AI128530NIAID NIH HHS R01 AI139102NIAID NIH HHS R01 AI191440NIAID NIH HHS T32 AI141393NIDDK NIH HHS R01 DK123528NIDDK NIH HHS R01DK123528NIDDK NIH HHS TL1 DK143326NIH HHS S10 OD023465Stiftelsen Blanceflor Boncompagni Ludovisi, född Bildt (Foundation Blanceflor Boncompagni Ludovisi, née Bildt)Swedish Society for Medical Research
6 · The paper itself
Abstract
Enteroinvasive bacterial pathogens are responsible for an enormous worldwide disease burden that critically affects the young and immunocompromised.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
TNF signaling maintains local restriction of bacterial founder populations in intestinal and systemic sites during oral · full record | OpenQuestion